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ABSTRACT
Synergy between transcription factors operating
together on complex promoters is a key aspect of
gene activation. The ability of specific factors to
synergize is restricted by sumoylation (synergy
control, SC). Focusing on the haematopoietic tran-
scription factor c-Myb, we found evidence for a
strong SC linked to SUMO-conjugation in its
negative regulatory domain (NRD), while AMV
v-Myb has escaped this control. Mechanistic
studies revealed a SUMO-dependent switch in the
function of NRD. When NRD is sumoylated, the
activity of c-Myb is reduced. When sumoylation is
abolished, NRD switches into being activating,
providing the factor with a second activation
function (AF). Thus, c-Myb harbours two AFs, one
that is constitutively active and one in the NRD
being SUMO-regulated (SRAF). This double AF
augments c-Myb synergy at compound natural pro-
moters. A similar SUMO-dependent switch was
observed in the regulatory domains of Sp3 and p53.
We show that the change in synergy behaviour cor-
relates with a SUMO-dependent differential recruit-
ment of p300 and a corresponding local change in
histone H3 and H4 acetylation. We therefore propose
a general model for SUMO-mediated SC, where
SUMO controls synergy by determining the number
and strength of AFs associated with a promoter
leading to differential chromatin signatures.
INTRODUCTION
Synergy between transcription factors is a well-known
phenomenon. Several models have been proposed to
explain this more-than-additive activity of multiple activa-
tors. Key concepts are multiplicity of contacts to the basal
transcription apparatus (1,2) promoting assembly of the
pre-initiation complex (PIC) (3), physical interactions
between transcription factors (4) particularly emphasized
in the enhanceosome model (5), co-activators harbouring
distinct domains that interact simultaneously with diﬀer-
ent factors (6) and cooperative interactions of transcrip-
tion factors with nucleosomal DNA (7). Activators able to
stimulate distinct steps in the transcription process, such
as initiation and elongation, may also contribute to con-
certed action and synergy (8). In general terms, synergy
appears to be intrinsic to the transcription process, being
related to the multiplicity of interactions necessary to
assemble an active PIC at the transcription start site
(TSS), triggering the productive elongation by RNA poly-
merase II. This makes synergy an ideal target for control
of transcriptional output.
An interesting twist to the phenomenon of synergy was
the ﬁnding of a speciﬁc negative control mechanism.
Iniguez-Lluhi and Pearce (9) identiﬁed a short protein
motif in the glucocorticoid receptor (GR) that mediated
‘synergy control’ (SC) by acting as a disruptor of synergy
on promoters with multiple response elements. Mutations
of this motif induced a strong synergistic behaviour of GR
at compound, but not at single, response elements. It soon
became apparent that the SC motif was a SUMO-
conjugation site and that the disruption of synergy was
caused by sumoylation of the factor at that site (10,11).
This role of SUMO (small ubiquitin-related modiﬁer) as a
disruptor of synergy has been extended to other transcrip-
tion factors such as SF-1, MITF and ZBP-89 (12–14).
Still, compared to the rapidly expanding literature on
SUMO only a tiny fraction of papers have addressed its
synergy-controlling properties.
The SUMO family proteins function by becoming co-
valently linked to a variety of proteins, including many
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nuclear transport, chromatin structure and DNA repair
(15,16). The modiﬁcation by SUMO is a highly dynamic
process, controlled by the balance between a set of conju-
gation enzymes, analogous to those of the ubiquitin
pathway and a set of SUMO-speciﬁc proteases.
The transcription factor c-Myb is a key regulator of
stem and progenitor cells in the bone marrow, colonic
crypts and a neurogenic region of the adult brain
(17,18). c-Myb becomes sumoylated at two sites within
its negative regulatory domain (NRD) leading to a
severe drop in its activity (19–21). Interestingly, both
SUMO-conjugation sites are deleted in the oncogenic
variant AMV v-Myb (19). The molecular mechanism by
which SUMO is controlling c-Myb activity is poorly
understood. Interestingly, synergy is a well-documented
aspect of c-Myb action. The factor has been reported to
activate promoters in synergy with several other transcrip-
tion factors such as Ets, C/EBPs, PU.1, Pax-5 and CBF
(core binding factor) (22–28) and being assisted by
co-activating factors such as p300, Mi-2a and FLASH
(25,29–32). Consistently, many of the genes activated by
c-Myb appear to be controlled by compound promoters
harbouring multiple recognition sites for both c-Myb and
other cooperating factors.
Given the role of SUMO as a disruptor of synergy for
some speciﬁc transcription factors, we reasoned that
studying its role in SC of c-Myb might lead to a better
understanding of the mechanisms by which SUMO
controls c-Myb action. In this work, we show that
c-Myb is subject to a strong SC, tightly linked to its
level of SUMO-conjugation, and that this control mech-
anism is abolished in AMV v-Myb. Chromatin-embedded
target genes of c-Myb respond diﬀerentially to
sumoylation in haematopoietic cells. We show that
SUMO aﬀects the synergistic behaviour of c-Myb by
switching oﬀ a SUMO-regulated activation function
(SRAF) in its NRD. This switch is reﬂected in a
SUMO-dependent change in the eﬃciency of p300 recruit-
ment to promoters. A similar SUMO-mediated switch in
the inhibitory domain (ID) of Sp3 and in the C-terminal
regulatory domain (CRD) of p53 indicates that this might
be a general mechanism by which SUMO controls tran-
scriptional synergy.
MATERIALS AND METHODS
Plasmid constructs
Plasmid constructs are outlined in Supplementary Data.
Cell culture, transfection and luciferase assays
CV-1, COS-1, HD11 and K562 cells were grown as previ-
ously described (31,32). HEK 293 cells, stably transfected
with a 5 Gal4-luciferase reporter (33), were grown in
DMEM (Invitrogen) supplemented with 10% fetal
bovine serum (FBS), penicillin, streptomycin and puro-
mycin. Cells were kept at 37 C in a humidiﬁed atmosphere
of 5% CO2 in air. The three ﬁrst cell lines were transiently
transfected with the indicated plasmids (0.2mg when
nothing else is given) using FuGENE6 (Roche Applied
Science) 24h after seeding. For the luciferase assays,
CV-1 cells were harvested 24h after transfection and
lysed in Passive Lysis Buﬀer (Promega). Luciferase
assays were performed in triplicate (24-well trays,
2   10
4 cells/well) using Luciferase Assay Reagent
(Promega). Data from at least three independent transfec-
tion experiments are presented.
Protein expression and GST pull-down
GST and GST-fusion proteins were expressed in
Escherichia coli as previously described (31). The regions
of human c-Myb expressed in the fusion proteins
GST-TAD, GST-NRD and GST-NRD 2KR spanned
amino acid residues 259–337 and 410–640, respectively.
The GST-NRD-SUMO1 corresponded to GST-NRD
with SUMO-1 (amino acid residues 1–96) fused in frame
to its C-terminal. GST pull-down assays were performed
as earlier described, using Frackelton-buﬀer [20mM
HEPES pH 7.4, 10% glycerol, 0.2% Triton X-100,
50mM NaCl, 30mM Na4P2O7, 50mM NaF, 2mM
Iodoacetate, 5mM ZnCl2, pH adjusted to 7.10, Protease
Inhibitor cocktail (Roche)] as lysis, interaction and
washing buﬀer (31). Electrophoretic mobility shift assay
(EMSA) was performed as outlined in Supplementary
Data.
Western blotting and antibodies
Cell lysates from transfected COS-1, CV-1, HD11, K562
and HEK 293 cells were subjected to western blotting.
Mouse anti-Myb 5e11 (31), rabbit anti-c-Myb H141
(sc-7874, Santa Cruz), rabbit anti-GAL4 (DBD, sc-577,
Santa Cruz), rabbit anti-HA (H6908 Sigma), mouse
anti-human p300 (33-7600, Zymed), mouse
anti-aTubulin (T9026, Sigma) and mouse anti-GAPDH
(H86504M Biodesign International) were used as
primary antibodies, while anti-mouse IgG-HRP (NA931,
GE Healthcare) and anti-rabbit IgG-HRP (NA934, GE
Healthcare) were used as secondary antibodies. For chro-
matin immunoprecipitation (ChIP) additional antibodies
were used: anti-FLAG M2 antibody (F3165, Sigma),
isotype control: anti-secretory Component (IgA) IgG1
(I6635, Sigma), anti-SETDB1 (ab12317-50, Abcam),
anti-Histone H3 trimethylated at lysine 9 (pAb-056-050,
Diagenode), anti-Mi2 (06-878, Millipore and sc-12547,
Santa Cruz), anti-acetyl-Histone H4 (06-866, Millipore),
anti-acetyl-Histone H3 (06-599, Millipore), anti-p300
(sc-585, Santa Cruz) and control IgG (ab46540, Abcam).
RNA isolation and quantitative RT–PCR
HD11 cells were transfected with 2mg DNA
(pCIneo-hcM-HA, pCIneo-hcM-2KR-HA or empty
pCIneo vector) per well in 6-well trays. Total RNA was
isolated and cDNA synthesized as previously described
(31). The cDNA obtained was subjected to real-time
PCR analysis (31) to determine the expression of two
c-Myb target genes: mim-1 and lysozyme, using the
LightCycler DNA MasterPlus SYBR Green Kit
(Roche). The relative amounts of the mRNAs were
normalized to the reference gene HPRT1. Primer se-
quences are available upon request.
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Human leukaemic K562 cells were stably transfected with
plasmids expressing 3 FLAG-c-Myb-HA wild-type and
2KR under the control of EEF1A1 promoter using the
Amaxa nucleofector kit. Single positive clones were
expanded and maintained in IMDM (Invitrogen) supple-
mented with 10% FCS and 200mg/ml G418 (Geneticin
from Gibco BRL Life Technologies, Inc).
Cells were cross-linked with 1% formaldehyde in PBS at
room temperature, K562 cells for 22min and HEK 293
cells for 15min. Cross-linking was performed with
rotation at room temperature, and the reaction was
stopped by addition of glycine to a ﬁnal concentration
of 125mM. After two washes with PBS, cells were lysed
in IP buﬀer {50mM Tris–HCl [pH 7.5], 5mM EDTA, 1%
Triton, 0.5% NP-40, 150mM NaCl, 0.1% SDS and
Complete
TM protease inhibitor cocktail tablets (Roche
Diagnostics)}. Samples were sonicated to generate
sheared DNA fragments around 400 base pairs (soluble
chromatin fraction), and insoluble chromatin was dis-
carded after centrifugation. Dynabeads
TM ProteinG were
washed with PBS and incubated with antibody at room
temperature for 40min followed by washing with PBS.
The soluble chromatin fraction was then added followed
by incubation overnight at 4 C with rotation. Chromatin
equivalent to typical 350000 cells was used per IP with
20ml Dynabeads
TM ProteinG and 2mg antibody, in a
total volume of 0.5ml IP buﬀer. The immunoprecipitates
were washed ﬁve times in IP buﬀer, before DNA was
eluted with 1% SDS in 100mM sodium carbonate at
65 C for 10min. After treatment with RNAse A and pro-
teinase K, cross-linking was reversed by incubation at
65 C for 6h. DNA was puriﬁed using silica columns
(Macherey-Nagel) and eluted in 50ml 10mM Tris–HCl
[pH 7.5]. Eluted DNA was used as template in quantita-
tive real-time PCR, in a 1:2 dilution in a total volume of
20ml (LightCycler 480 SYBR Green I Master, Roche
Diagnostics). Standard curves of genomic DNA were
run alongside the ChIP samples for each primer pair,
and analyzed on a LightCycler 480 (Roche
Diagnostics). Input DNA was used to normalize values
from ChIP samples.
RESULTS
Synergy behaviour of c-Myb and its relation to
SUMO-conjugation
Previous studies have reported that the activity of c-Myb
is signiﬁcantly enhanced by removal of its two
SUMO-conjugation sites (19,20). To better understand
the mechanism of this enhancement, we asked whether
c-Myb was subject to the phenomenon of SC.
Systematic analysis of this type of behaviour requires a
dedicated set of reporter constructs with deﬁned changes
in the multiplicity of response elements. Hence, we con-
structed a set of reporter plasmids based on the pGL3
backbone with identical core promoters (from MYC P2),
activated by one to ﬁve copies of an optimal
Myb-response element (MRE) each with a phasing of
10bp (Figure 1A). Binding to diﬀerently spaced MREs
was examined in a systematic EMSA study using recom-
binant c-Myb. Here, we observed that a phasing of 6bp
caused interference from one bound factor on the binding
of a second, while a phasing of 10bp did not (Figure 1B).
When reporters with one to ﬁve MREs were compared,
wild-type c-Myb activated the various reporters with only
minor diﬀerences (all about 3-fold) suggesting a modest
response to increasing multiplicity (Figure 1C). In
contrast, the SUMO-conjugation negative mutant,
c-Myb 2KR, showed a remarkable increase in activity
when the number of MREs was augmented (Figure 1C).
In order to quantify this diﬀerence in synergistic behav-
iour, we deﬁned a relative ‘synergy factor’ (SF) as the ratio
of the reporter activity with four MREs to the activity
with one MRE, divided by four (the latter to obtain
ratios independent on the number of MREs). A simple
proportional increase in reporter activity with the
number of MREs should then give an SF=1, while a
positive synergy will result in SF>1. An SF<1 would
then imply a less than additive eﬀect, which might be
termed ‘negative synergy’ (illustrated in Figure 1D). We
calculated the SF based on four MREs in this work, but
very similar SFs were obtained when we calculated ratios
based on three or more MREs (data not shown). It should
be noticed that SF is a relative quantity showing little
dependence on the expression level of the factor tested.
Using this simple quantiﬁcation scheme, we compared
wild-type and mutant c-Myb (Figure 1E). In fact,
wild-type c-Myb displayed a negative synergy
(SF = 0.26), while the SUMO-negative c-Myb 2KR
showed a strong positive synergy (SF = 3.9). Single
mutants, retaining one of the two SUMO-conjugation
sites, showed intermediate levels (K503R: SF = 0.98,
K527R: SF=0.72). By comparing the SF data for the
SUMO mutants (Figure 1E, upper panel) with their modi-
ﬁcation pattern (Figure 1E, lower panel), it seems clear
that SF is inversely related to the level of c-Myb
sumoylation. It may be noticed that the multiple bands
representing one (c-Myb 1S) or two (c-Myb 2S)
conjugated SUMO-moieties appear to be caused by
various states of phosphorylation (data not shown).
Taken together, these results suggest that the synergistic
behaviour of c-Myb is highly dependent on its ability to
become sumoylated.
In the reporters used to calculate SF values, the phasing
of the MREs causes the bound c-Myb activators to have
the same helical orientation on the promoter (marked cis
in Figure 1F). We designed a 4 MRE reporter with a
phasing of 15bp to give an alternating helical orientation
(marked trans in Figure 1F). While the SF values obtained
with the SUMO-negative c-Myb 2KR did not change with
helical orientation, the lower values obtained with
wild-type c-Myb did, in fact, change. The level of
‘negative synergy’ became more relaxed when the helical
orientation became alternating (SF = 0.83) compared to
when all elements were oriented on the same side of the
DNA helix (SF = 0.26). This may reﬂect a diﬀerent co-
operation mechanism responsible for generating positive
synergy as compared to the mechanism restricting
synergy.
4972 Nucleic Acids Research, 2010,Vol.38, No. 15Figure 1. A SUMO-mediated SC is operating on c-Myb. (A) Schematic picture of the diﬀerent EMSA probes used to identify the minimal phasing
between the MREs, and the luciferase reporters used in this study. The reporter plasmids contained increasing numbers of MREs (1  to 5 , all with
10bp phasing) upstream of a core promoter from human MYC driving the luciferase reporter gene. (B) Recombinant c-Myb DBD (R123: 0–25fmol)
was bound to 2 MRE(GG) oligonucleotides (20fmol each) with diﬀerent phasing (6, 10, 15 or 20bp) and complexes were separated on EMSA gels.
F, free probe; */**, one or two R123 molecule(s) in complex with the probe, respectively. (C) CV-1 cells were transfected with reporter plasmids
containing increasing numbers of MREs (1  to 5 ) as indicated and a plasmid encoding c-Myb wild-type (inverted ﬁlled triangle) or a
SUMO-negative c-Myb 2KR (ﬁlled diamond). Reporter activation is presented as relative luciferase units (RLU) ± SEM. (D) The deﬁnition of
the SF. (E) CV-1 cells were transfected with reporters containing one or four MREs [(1 MRE(GG)-MYC or 4 MRE(GG)-MYC] and plasmids
encoding c-Myb wild-type, c-Myb with both SUMO-conjugation sites mutated from lysine to arginine (2KR) or single SUMO-conjugation sites
mutated (K503R/K527R, upper panel). CV-1 cells were co-transfected with plasmids encoding the diﬀerent c-Myb SUMO-mutants and PIASy (ratio
4:1) to visualize the sumoylation pattern. The cells were lysed directly in SDS–PAGE loading buﬀer to maintain the modiﬁcations (lower panel).
c-Myb-S and c-Myb-2S: c-Myb modiﬁed with one or two SUMO moieties, respectively. (F) SFs were measured using wild-type c-Myb and c-Myb
2KR expression plasmids together with two variants of a luciferase reporter activated by four MREs, diﬀering only in their helical phasing. In the cis
reporter, pGL4-4 MRE(GG)-MYC, the MRE phasing is 10bp, while in the trans reporter, pGL4-4 MRE(GG)-MYC abab, the MRE phasing is
15bp. The results are presented as SF±SEM.
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and sumoylation further, we asked whether the strong
synergy of c-Myb 2KR would be reduced by SUMO-1
covalently fused to its C-terminal. As shown in
Figure 2A, the c-Myb-2KR-SUMO-1 fusion gave a
strong reduction in synergy (SF=0.95) when compared
to the non-fused 2KR protein (SF=3.9). This SF reduc-
tion was not due to alterations of the protein levels
(Figure 2A, lower panel). The SF value of the
SUMO-fusion is in fact very similar to the SF of the
single mutants (K503R and K527R, Figure 1E) also har-
bouring one SUMO moiety in their conjugated state.
We also studied the eﬀect of alternative mutations
(KXE ! KXA) known to abolish SUMO-
conjugation, while allowing other Lys-directed modiﬁca-
tions to take place (34). The 2EA mutant (E505A+E529A)
caused a strong increase in synergy (SF=2.5, Figure 2B).
The oncogenic activated AMV v-Myb harbours
both point mutations and N- and C-terminal deletions,
the last one removing both SUMO-conjugation sites.
We expected the latter deletion to aﬀect the synergy be-
haviour of v-Myb. The cumulative eﬀects of the other
mutations, however, were less predictable in a synergy
assay. As shown in Figure 2C, v-Myb in fact displayed
the strongest synergy of all Myb-variants tested so far
(SF=4.8), which suggests that escaping synergy control
Figure 2. The level of synergy is highly dependent on the sumoylation status of c-Myb. CV-1 cells were transfected with reporters containing one or
four MREs [1 MRE(GG)-MYC or 4 MRE(GG)-MYC] and plasmids encoding (A) c-Myb wild-type, c-Myb 2KR or a 2KR-mutant fused to
SUMO-1, (B) c-Myb wild-type, c-Myb with individual SUMO-conjugation sites mutated from glutamate to alanine (E505A, E529A) or with both
sites mutated (2EA), (C) c-Myb wild-type or the oncogenic version AMV v-Myb, or (D) c-Myb wild-type or a SUMO-negative c-Myb 2KR, with or
without the SUMO-protease SENP1 or SENP1 mutant as indicated. The results are presented as SF±SEM. Western controls shown in (A) were
analyzed using anti-c-Myb (5E11) and anti-GAPDH antibodies. (E) CV-1 cells were co-transfected with a plasmid encoding c-Myb wild-type (1.0mg)
and either SENP1 or SENP1 mutant (0.25 or 0.50mg) to visualize changes in the sumoylation pattern. The cells were lysed directly in SDS–PAGE
loading buﬀer to maintain the modiﬁcations. c-Myb-S and c-Myb-2S: c-Myb modiﬁed with one or two SUMO proteins, respectively.
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Finally, the desumoylation of c-Myb induced by ectopic
expression of the SUMO-protease SENP1 enhanced the
synergy behaviour of wild-type c-Myb (SF increased
from 0.26 to 2.8), while a protease-dead SENP1 had
no eﬀect (Figure 2D). As expected, the synergy behaviour
of c-Myb 2KR was not inﬂuenced by SENP1.
Co-expression of SENP-1 wild-type, but not the mutant,
shifted the balance towards desumoylation of c-Myb
(Figure 2E), conﬁrming that SENP-1 is a relevant
SUMO protease for c-Myb under these experimental con-
ditions. Taken together, these data suggest that
SUMO-conjugation is the major determinant of synergy
behaviour of c-Myb as revealed by this MRE-multiplicity
assay.
Relevance of SC to resident promoters
Most natural promoters are complex and often activated
by a combination of transcription factors, several of which
may be SUMO-conjugated. The activation of a natural
promoter through desumoylation would be expected to
involve removal of SUMO from various transcription
factors. Unfortunately, this situation is not easy to
mimic in an experimental setup. However, two
Myb-responsive genes have been characterized in detail
with respect to chromosomal organization of their
Myb-responsive regulatory regions (Figure 3A). The
mim-1 gene is activated by c-Myb through interaction
with two distinct regions, a promoter and an enhancer
region, both of which contain several MREs (35,36).
The lysozyme gene has a similar organization but with
fewer active MREs involved (36,37). Hence, we addressed
the physiological relevance of the SUMO-mediated SC of
c-Myb by comparing the activation of these two endogen-
ous target genes by wild-type c-Myb and c-Myb 2KR,
both expressed to similar levels (Figure 3B). We used
c-Myb negative chicken macrophage HD11 cells since
these cells express C/EBPb known to cooperate with
c-Myb in transcriptional activation of both mim-1 and
lysozyme (24,38). As shown in Figure 3C, co-transfection
of c-Myb wild-type or 2KR mutant resulted in a clear
diﬀerential activation of mim-1, as expected if several
MREs contribute to the activity of the chromatin
embedded promoter. For the lysozyme gene (Figure 3D),
the diﬀerence between c-Myb wild-type and 2KR was
much less pronounced, consistent with fewer MREs
being involved. We conclude that natural promoters
diﬀer signiﬁcantly in their synergy behaviour when
c-Myb is compared in the two states. We expect,
however, that a larger diﬀerence would have been
observed if we had been able to compare two or more
cooperating factors in both SUMO-conjugated and
non-conjugated states.
Figure 3. Diﬀerent c-Myb-mediated synergy on natural chromatin-embedded promoters. (A) Schematic presentation of the regulatory elements of
the mim-1 and lysozyme genes according to (35–37). Both genes contain functional MREs in enhancer elements as well as in promoters. Question
mark indicates functionality uncertain. HD11 cells were transfected with plasmids expressing c-Myb-HA or the sumoylation-negative mutant
c-Myb-2KR-HA. (B) A western blot performed with anti-HA antibody, using lysates from the same cultures used for activity measurements. The
a-tubulin was used as loading control. Activation of the endogenous Myb-target genes (C) mim-1 and (D) lysozyme was measured by quantitative
real-time PCR. Target gene expression data were normalized by the relative expression of the housekeeping gene HPRT1 and represented as relative
to empty vector-transfected cells, which were set to 100. The results represent the mean±SEM of three independent biological assays, each analysed
in duplicate for expression levels.
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Being conﬁdent that the synergy property of c-Myb is
controlled by SUMO, we asked what mechanism might
be involved. First, we explored SUMO-induced changes
in intrinsic properties of c-Myb, i.e. whether
SUMO-conjugation converts c-Myb into a less
synergizing factor by causing either reduced speciﬁc
DNA binding or impaired transactivation properties.
Secondly, we explored altered interactions, i.e. whether
SUMO-conjugation might, by adding a new interaction
surface, change the recruitment of co-factors to c-Myb.
An EMSA analysis showed that the speciﬁc DNA
binding observed was similar for c-Myb wild-type and
2KR as well as for the SUMO-fusion protein
(Supplementary Figure S1), indicating that SUMO
moieties conjugated or fused to the C-terminal of c-Myb
have no signiﬁcant inﬂuence on the activity of the DNA
binding domain localized in the N-terminal of the protein.
To monitor the DNA binding in vivo, we analysed c-Myb
occupancy on the endogenous MYC promoter, an estab-
lished target gene of c-Myb, harbouring multiple MREs
[(39) and references therein]. For this analysis, we
generated stable cell lines derived from K562 with
integrated double-tagged c-Myb constructs in both
wild-type and 2KR mutant versions. The levels of expres-
sions of c-Myb in these cells are very close to the endogen-
ous gene product and thus represent physiological levels of
c-Myb (see western-insert in Figure 4). The ChIP signals
were highly similar for the two versions of c-Myb, suggest-
ing no signiﬁcant diﬀerence in chromatin occupancy
between wild-type and 2KR c-Myb (Figure 4). We also
tested the same MYC promoter region in a reporter
assay and found c-Myb 2KR to activate this promoter
signiﬁcantly stronger than wild-type c-Myb did, conﬁrm-
ing the relevance of this promoter for SC (Supplementary
Figure S2). Taken together, these data do not support an
explanation of the SUMO-induced change in synergizing
properties of c-Myb based on changes in DNA binding
properties, neither in vitro nor in vivo.
SUMO controls an activator-to-repressor switch
in c-Myb NRD
The NRD of c-Myb obtained its name from the early
observation that a C-terminal deletion in mouse or
chicken c-Myb (similar to that found in AMV v-Myb)
created a more active factor (40,41). The same is true for
human c-Myb. We found human c-Myb-NRD to be
much more active than the full-length protein (bar 3
versus bar 1 in Figure 5A), probably due to the loss of
the SUMO-conjugation sites in NRD. However, we
noticed that the same deletion, when compared to the de-
repressed SUMO-negative 2KR-version of c-Myb (bar 3
versus bar 2 in Figure 5A), created a less active factor
suggesting that NRD in the absence of SUMO-
conjugation might harbour an activation function (AF).
If so, the c-Myb 2KR has not only lost its internal repres-
sor function but also behaves like a protein with an
added AF.
The classical way of identifying an AF is by fusing the
domain under investigation to the Gal4p DBD and moni-
toring the induced activation of a Gal4p-responsive
reporter. When we tested the NRD region of c-Myb
(amino acids 410–640) in such a system, we saw that the
wild-type version of NRD had a weak repressive eﬀect
(Figure 6A). However, the SUMO-negative 2KR version
of NRD was no longer acting negatively, but had switched
into behaving as an activator (Figure 6A). To make sure
that this notable observation was not some peculiarity
related to the minimal E1B promoter in the pG5E1bLuc
reporter used, we repeated the experiment with an
SNRPN-driven Gal4p-responsive luciferase reporter and
observed an equal eﬀect (data not shown). We also tested
out the E!A mutants instead of the K!R mutants and
observed the same changes in the properties of the NRD
becoming an activating domain upon reduced
sumoylation (Figure 6A). The fusion of SUMO-1 to the
active 2KR-version of the NRD abolished its AF totally.
All Gal4p-DBD fusion constructs showed equal expres-
sion levels as evaluated by western (data not shown)
Figure 4. c-Myb occupancy on the MYC promoter is
SUMO-independent. ChIP were performed with K562 cells to assess
occupancy of c-Myb wild-type and SUMO-negative 2KR-mutant on
the human MYC promoter. K562 cells were stably transfected with
3 FLAG- and HA-tagged c-Myb wild-type and 2KR, and clones
were picked based on immunoblotting (inserted panel) showing
similar expression of the integrated and endogenous c-Myb. ChIP
was performed using anti-FLAG antibody, while an isotype IgG
antibody was used as negative control. Occupancy was analysed by
amplifying the MYC promoter by real-time PCR after reversal of the
cross-linking. An unrelated DNA region (UDR) was used as negative
control. The UDR was chosen from the gene desert region (53), the
exact location is: chr2: 22153688+22153788. The results are calculated
from triplicates of real-time PCR reactions and are expressed as per-
centage of recovery±SD relative to the input. v, stable cell lines with
integrated empty vector pEF1neo; asterisk, endogenous c-Myb; double
asterisk, stably integrated, double-tagged c-Myb.
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strong increase in synergy properties as observed when
SF-values were measured for all the Gal4p-fusions using
a1  GRE reporter in addition to the 5 GRE reporter
(Figure 6B).
Finally, we analyzed Gal-NRD fusion proteins in the
presence of overexpressed SENP1. As shown in Figure 6C,
this SUMO-protease was able to induce the functional
switch of the NRD from being a weak repressor to a
positive activator. While the wild-type NRD changed
50-fold in activity upon overexpression of SENP1, the
already derepressed 2KR version did not increase
more than the background. As expected, this functional
switch was accompanied by a large change in SF-values
(data not shown).
The model implicated from these ﬁndings is that c-Myb
has two AFs, one constitutively active, centrally located in
the protein (TAD) and a second SRAF in the NRD
region, functioning as an internal repressor in the
wild-type protein (illustrated in Figure 5A). To test this
model further, we reasoned that if the NRD contains a
SRAF, which becomes active upon removal of
SUMO-conjugation, we should be able to rescue a
defect introduced in c-Myb caused by deletion of its con-
stitutive central transactivation domain, simply by
activating its silenced SRAF in NRD. In Figure 5B, we
have compared c-Myb wild-type, c-Myb with its central
TAD deleted and c-Myb with the TAD-deletion in com-
bination with the 2KR mutation. Clearly, the expected
rescue is observed showing that also in the full-length
protein the NRD can be activated providing a second
AF, which will contribute to the overall transactivation
potential of the c-Myb protein. In parallel with this
rescue, we observed an increase in synergy properties
(Figure 5C).
Activators with two AFs are known from the literature,
the steroid hormone receptor family being one prominent
example. In fact, SC was ﬁrst found in members of this
family (9). To test whether the SUMO-dependent
repressor-to-activator switch is a more general phenom-
enon, we chose to study the Sp3 transcription factor
because this factor has been reported to activate or
repress transcription depending on the promoter context
(42). Moreover, the repressive function of Sp3 is mediated
Figure 5. Evidence for two AFs in c-Myb. CV-1 cells were transfected with a Myb-responsive reporter plasmid containing three or four MREs
(0.2mg) as indicated and (A) 0.4mg of plasmids encoding either full-length c-Myb, its SUMO-conjugation negative mutant c-Myb-2KR, or a deletion
variant c-Myb NRD, or (B) full-length c-Myb, a variant with the central transactivation domain deleted (c-Myb-T1) and SUMO-negative c-Myb
with TAD deleted (c-Myb-T1-2KR). The results are presented as RLU±SEM. Western controls shown in (A) and (B) were analysed using anti-c-
Myb (5E11) and anti-GAPDH antibodies. The numbers under each lane/bar correspond to the constructs shown in the lower boxes, V: empty vector.
(C) CV-1 cells were transfected with reporters containing one or four Myb responsive elements [1 MRE(GG)-MYC or 4 MRE(GG)-MYC] and
plasmids encoding c-Myb-T1 or c-Myb-T1-2KR. The results are presented as SF±SEM.
Nucleic Acids Research, 2010,Vol.38, No. 15 4977by SUMO-conjugation of K551 located in an ID. First,
we conﬁrmed using our Gal4-responsive reporter that
mutation of its SUMO-conjugation site turned a
Gal4p-Sp3 fusion protein into an activator (Figure 7A)
as reported (42). This was accompanied by a large
increase in SF value indicating a parallel change in
synergy properties (Figure 7B). Next, we asked whether
the small ID region harbouring the sumoylation site when
removed from its two glutamine-rich activation domains
would show SRAF behaviour. As seen for c-Myb NRD,
wild-type Sp3-ID had a weak repressive eﬀect by itself,
while the SUMO-negative version was clearly activating
(Figure 7C), showing the presence of a SRAF in Sp3. In
parallel, we measured a large increase in SF value for
SUMO-negative Sp3-ID (Figure 7D), linking the func-
tional switch to changes in synergy behaviour. We also
extended our analysis to the sumoylated CRD in p53.
Again, we observed a similar change, but with more
modest alterations (Supplementary Figure S3).
Synergy and number of AFs
Given that SUMO-conjugation suppresses a second AF in
c-Myb, it appears quite probable that derepression of this
SRAF upon removal of SUMO makes an important con-
tribution to the enhanced synergy of c-Myb 2KR. An
obvious model, combining the synergy properties of the
c-Myb variants and the switch-property of NRD, would
be that the eﬃciency of synergy as measured by the SF,
relates to the number and strength of independent AFs
brought to a promoter through the bound transcription
factors. If this is correct, we should be able to measure
increasingly larger SFs for c-Myb variants harbouring
increasing number (and strengths) of AFs. To test this
hypothesis, we measured SFs for two additional c-Myb
variants: a c-Myb-VP16 fusion protein (harbouring two
AFs linked to one repressive NRD function), and
c-Myb-2KR-VP16 (harbouring three AFs). These were
compared with wild-type c-Myb (harbouring one partially
repressed AF), c-Myb NRD (harbouring one AF) and
c-Myb 2KR (harbouring two AFs). As shown in Figure 8,
we observed the expected SF increase when number and
strengths of AFs were increased. The deletion c-Myb
NRD, with one AF relieved from the repressive inﬂu-
ence of NRD, gave a higher SF than both wild-type and
c-Myb-VP16, but still well below that of c-Myb 2KR har-
bouring two AFs. The c-Myb-2KR-VP16 fusion protein,
harbouring three AFs, showed an extremely large SF of
35. This variant was in fact 140-fold more active on a
promoter with four MREs than on a promoter with a
single MRE.
Figure 6. The NRD region of c-Myb harbours a SRAF that can switch
from being repressive to be activating. (A) CV-1 cells were transfected
with 0.2 or 0.4mg of plasmids expressing Gal4p-DBD (GBD) fused to
c-Myb NRD (amino acid residues 410–640) wild-type, 2KR,
WT-SUMO-1, 2KR-SUMO-1 or 2EA. The reporter output from the
E1b-driven Gal4p-responsive reporter plasmid (5 GRE, 0.2mg) was
normalized to the eﬀect of Gal4p-DBD (0.2 or 0.4mg), which was set
to 100. The results are presented as RLU ± SEM. (B) Based on
parallel transfections, using an 1 GRE-E1b-Luc reporter plasmid
(0.2mg), the SFs of the constructs assayed in (A) were calculated.
The results are presented as SF±SEM. (C) CV-1 cells were transfected
with plasmids expressing GBD, GBD-NRD or GBD-NRD-2KR
together with the SUMO-protease SENP1 or a protease-dead SENP1
mutant. The results are presented as fold change±SEM, relative to the
activity levels of the GBD constructs in the absence of the protease.
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Having explored how SUMO-conjugation aﬀects intrinsic
properties of c-Myb, we next investigated SUMO-
modulated interactions. To assess interactions in the
context of multiple SUMO-conjugated c-Myb proteins
bound to a chromatinized promoter, we took advantage
of the model system developed by Suske and co-workers
(33), in which an array of Gal4-responsive elements
(5 GRE) in front of a luciferase reporter is integrated
in the genome of HEK 293 cells (Figure 9A). First, we
made Gal4-c-Myb fusion constructs of the same design
as used previously for Sp3 (33), with the c-Myb DBD
replaced by Gal4-DBD (Figure 9A). Reporter assays
showed a dramatic SUMO-dependent switch in activation
in this system, with wild-type c-Myb showing quite modest
activation and the SUMO-negative c-Myb 2KR behaving
as a potent activator of the integrated reporter, being
about 900-fold more active than wild-type c-Myb
(Figure 9B, lower panel). Both forms of c-Myb were
equally expressed (Figure 9B, upper panel). For compari-
son the sumoylation-deﬁcient Gal4-Sp3-KEE mutant
versus wild-type Gal4-Sp3 also showed a
SUMO-dependent shift, but only about 10-fold (Figure
9C). Notably, the level of activation observed with
sumoylation-competent Gal-Myb was comparable to
that seen with sumoylation-deﬁcient Gal4-Sp3-KEE
(Figure 9C). ChIP analysis of c-Myb occupancy conﬁrmed
equal binding of both forms of c-Myb to the promoter
region (Figure 9D). This is consistent with what we
observed in the EMSA studies (Figure 1B and
Supplementary Figure S1) and on the MYC promoter
(Figure 4), conﬁrming that SUMO-status does not aﬀect
the promoter recruitment of c-Myb.
Since the sumoylation-competent Gal-Sp3 repressor in
the reporter cell line studied here has been shown to
induce a local repressive chromatin state through recruit-
ment of factors associated with heterochromatin forma-
tion (33), we addressed whether the same factors were
diﬀerentially recruited by the two forms of c-Myb tested
in this system. However, consistent with the activation
proﬁles, neither form of c-Myb appears to behave like
Gal-Sp3, but rather like the activating Gal-Sp3-KEE.
We were not able to detect c-Myb-mediated recruitment
of SETDB1, nor observe signiﬁcantly diﬀerent levels of
H3K9me3 associated with the promoter (results not
shown). We performed a ChIP-analysis of endogenous
Mi-2, but could not detect any enrichment at the
promoter (data not shown). Assaying transfected Mi-2a,
we observed a c-Myb-dependent recruitment to the
promoter, but no diﬀerential SUMO-dependent recruit-
ment (Figure 9E). This is consistent with our previous
observation that Mi-2a has aﬃnity for c-Myb (31),
which in this case may override a SUMO-mediated
recruitment.
Figure 7. The ID in Sp3 harbours a SRAF. CV-1 cells were transfected
with 0.2mg of plasmids expressing Gal4p-DBD fused to (A) Sp3 (amino
acid residues 81–613) wild-type or the kee SUMO-negative mutant, or
(C) Sp3 ID (amino acid residues 534–612) wild-type and kee mutant.
The reporter output from the E1b-driven Gal4p-responsive reporter
plasmid (5 GRE, 0.2mg) was normalized to the eﬀect of Gal4p-DBD
(0.2mg) and set to 100. The results are presented as RLU±SEM. (B
and D) Based on parallel transfections, using an 1 GRE-E1b-Luc
reporter plasmid (0.2mg), the SFs for the GBD-Sp3 and
GBD-Sp3-ID constructs assayed in (A) and (C) were calculated. The
results are presented as SF±SEM.
Figure 8. The importance of the number of AFs for level of synergy.
CV-1 cells were transfected with reporter plasmids containing one or
four MREs (1 MRE(GG)-MYC or 4 MRE(GG)-MYC) and an
eﬀector plasmid encoding one of the following c-Myb variants:
c-Myb, c-Myb-NRD encoding amino acids 1–443, the SUMO-
conjugation negative mutant c-Myb-2KR, as well as c-Myb and
c-Myb-2KR fused C-terminally to the herpes simplex virus VP16 trans-
activation domain. The results are presented as SF±SEM.
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the Gal-Myb proteins relative to the Gal-Sp3 proteins
(Figure 9C), we turned to analysis of co-activator recruit-
ment. Interestingly, the endogenous p300 co-activator
showed a clear diﬀerential recruitment, as revealed by a
signiﬁcantly higher occupancy in the presence of the
sumoylation-deﬁcient Gal-Myb 2KR compared to
wild-type Gal-Myb (Figure 9F). This behaviour is consist-
ent with the observation that Gal-NRD 2KR is
p300-responsive while Gal-NRD is not (Supplementary
Figure S4A and B). We therefore assume that the
SUMO-negative NRD (SRAF in ON-state) contributes
to the observed diﬀerential recruitment of p300,
although its contribution may be indirect involving add-
itional co-activators (Supplementary Figure S4C). A ChIP
analysis of the acetylation status of the promoter showed a
parallel increase in histone H3 and H4 acetylation when
sumoylation was abolished and p300 occupancy enhanced
(Figure 9G and H), consistent with a p300-induced acetyl-
ation pattern (43).
We conclude that the SC of c-Myb is strongly coupled
to SUMO-conjugation of c-Myb. When c-Myb is being
sumoylated, its recruitment to promoters is not aﬀected,
but its SUMO-status will obstruct synergy and hinder its
full transactivation potential to be unleashed. Removal of
SUMO-conjugation triggers the potential of c-Myb to
synergize on compound promoters. One important contri-
bution to this increased synergy appears to be the dere-
pression of a silenced AF in the NRD of c-Myb becoming
active upon removal of SUMO-conjugation. This leads to
a more eﬃcient recruitment of the co-activator p300 and
increased histone H3/H4 acetylation. In this manner, the
SRAF switch makes an important contribution to the
large diﬀerences observed between wild-type and
SUMO-negative c-Myb on complex promoters.
DISCUSSION
Synergy is an inherent property of the transcription
system being related to the multiplicity of interactions ne-
cessary to assemble an active PIC at the TSS to allow the
productive elongation by RNA polymerase II. Any modu-
lations of the many weak interactions may cause a large
change in output. Thus, the phenomenon of synergy
appears to be an ideal target for transcriptional control.
We have in this work shown that c-Myb, which appears to
be a rather weak activator, has an inherent potential to
become a quite strong one. This property is revealed by
three phenomena studied here. First, removal of
SUMO-conjugation in c-Myb unleashes the potential of
c-Myb to synergize on compound promoters. The larger
the number of MREs, the larger the diﬀerence in
Figure 9. SUMO-dependent recruitment to chromatin. (A) ChIPs were
performed in a HEK 293 reporter cell line (33) harbouring an
integrated transgene as illustrated [drawing based on Fig.2 in ref.
(33)]. The reporter cell line was transfected with Gal-fusion derivatives
of c-Myb as illustrated. Occupancy of factors and presence of chroma-
tin marks were assessed on the luciferase promoter 5 Gal4 responsive
elements (5 GRE) and on an intronic element in the neighbouring
NCOA5 gene. Arrows indicate the regions ampliﬁed during analysis
of ChIP samples by quantitative real-time PCR (ChIP–qPCR). (B)
HEK 293 cells were transfected with plasmids expressing Gal4p-DBD
(GBD) fused to c-Myb (amino acid residues 233–640) wild-type or
2KR. The output from the integrated luciferase was normalized to
the eﬀect of GBD alone, which was set to 100. The results are pre-
sented as RLU±SEM. Immunoblotting was performed to control
protein expression. Cells were lysed directly in SDS–PAGE loading
buﬀer to maintain the modiﬁcations, and analysed using anti-HA
antibody. GBD-Myb 1S and 2S: GBD-c-Myb modiﬁed with one or
two SUMO proteins, respectively. (C) HEK 293 cells were transfected
with plasmids expressing Gal4p-DBD fused to c-Myb wild-type, Sp3
wild-type or the kee SUMO-negative mutant of Sp3. The luciferase
output was treated and presented as in (B). Occupancies of (D)
Gal-Myb, (E) Mi-2a,( F) p300, (G) acetylated histone H3 and (H)
acetylated histone H4 on the 5 GRE promoter and on the NCOA5
intron were analysed using ChIP–qPCR with cells transfected with
GBD-Myb wild-type, 2KR or empty vector. In (E) Gal-Myb was
co-transfected with FLAG-tagged Mi-2a.
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c-Myb and its SUMO-conjugation negative mutant. All
experimental modulations that changed the level of
SUMO-conjugation led to the expected changes in
synergy behaviour, ﬁrmly linking the ability of c-Myb to
synergize with its sumoylation status. We further show
that a major contribution to the increased synergy
caused by SUMO-removal is the derepression of a
silenced AF in the NRD of c-Myb. This domain is able
to switch from functioning as an internal repressor into
functioning as an activator upon removal of
SUMO-conjugation. Our data suggest a new model for
c-Myb in which the factor has two AFs, one in the estab-
lished central TAD acting in a constitutive fashion and a
second inducible AF, designated SRAF, being repressed
by SUMO-conjugation. The latter provide c-Myb with an
inherent potential to change from a rather weak activator
into a potent transactivating factor harbouring a double
set of AFs. The dual function of the C-terminal region of
c-Myb merits a change in designation from NRD to CRD.
Finally, we show that this switch leads to a more eﬃcient
recruitment of the p300 co-activator to compound
chromatin-embedded promoters, changing the local signa-
ture of histone modiﬁcations.
The link between the ability of a transcription factor to
synergize on complex promoters and the factor being
relieved from SUMO-conjugation was ﬁrst observed in
studies of the GR (9,10) and later extended to other
factors such as C/EBPa, SF-1, MITF, and recently
ZBP-89 (12–14,44). We show in this work that c-Myb
may be added to the growing list of synergy-controlled
transcription factors.
Concerning synergy control mechanisms, several
possibilities have been proposed, such as SUMO-
mediated recruitment of co-repressors (9,10) to explain
the repressive aspects. A signiﬁcant advance in our under-
standing here comes from the recent works from Suske
and co-workers (33,45) showing that a set of identiﬁed
repressor proteins acts together to set up a local hetero-
chromatin structure dependent on SUMO. However, there
may be a larger diversity of mechanisms here than
revealed by the action of Sp3 as exampliﬁed by the
SUMO-dependent recruitment of HDACs (46,47),
CoREST1 (48) and KAP1 (49). Still, the common theme
appears to be that sumoylation plays a key role in
coordinating histone modiﬁcations and chromatin struc-
ture, which explains its eﬀect on transcription and on
synergy. In the present work, we add three elements to
a model that may explain the phenomenon of
SUMO-mediated SC. First, we emphasize that the
synergy behaviour observed points to multiplicity as an
important aspect that has to be incorporated into the
mechanistic model. Second, we show that sumoylated
domains may be repressed activation domains that
switch function upon desumoylation. Finally, we present
evidence for a SUMO-dependent diﬀerential recruitment
of co-activators leading to a change in the histone modi-
ﬁcation pattern.
Figure 10 illustrates some key elements in a model of
transcriptional synergy. In the sumoylated state, synergy is
restricted either because of a SUMO-induced blocking of
Figure 10. A model for SRAF and SC. (A) A model for the repressed
state, where SUMO-conjugation disrupts the interaction with the
co-activator. (B) A model for the repressed state where multiple
SUMO-conjugated factors recruit a multivalent co-repressor; SCF,
synergy control factor (9). (C) Traditional concept of synergy
mediated by joint recruitment of a multivalent co-activator. (D)
Current model for the activated state where multiple AFs (depicted
as stars) per transcription factor lead to more eﬃcient recruitment of
a multivalent co-activator. (E) A variant of the model above (D) where
diﬀerent AFs may interact with diﬀerent co-activators.
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a SUMO-induced generation of repressive interactions
(Figure 10B). A combination of both is also quite likely.
The recruitment of repressors to chromatin ﬁts very well
with the model of SUMO-mediated heterochromatin for-
mation (33), as well as with other repressor studies (50).
Although not emphasized in the model, the work on
SUMO-governed hetrochromatic formation (33) was per-
formed with the same integrated, multimerized
Gal4-responsive reporter gene as in this study. Thus, we
would not be surprised if some of the co-repressors
reported in Suske’s study turn out to have a preference
for arrays of SUMO-conjugated factors. The active syn-
ergistic state would require removal of SUMO, which may
be either a stochastic process caused by the unstable
sumoylated state or a more directed process through
signal-induced recruitment of SUMO-proteases.
Our identiﬁcation of the SRAF phenomenon, where the
NRD region of c-Myb as well as the ID of Sp3 and
possibly the CRD of p53 have the particular ability to
switch from acting negatively to acting positively depend-
ing on sumoylation status is a novel element that adds to
our mechanistic understanding. We propose that positive
synergy is determined by the number and strength of in-
dependent AFs associated with a promoter through the
bound transcription factors. Under conditions of normal
sumoylation, c-Myb contains one AF (in TAD) partially
repressed by the sumoylated NRD and the level of synergy
is rather low (SF=0.26). Upon reduced sumoylation, as
mimicked in the 2KR mutant or by ectopic expression of
SENP1, the second AF is turned on and the central TAD
is relieved of its repression. Now, c-Myb will operate with
two AFs and show higher synergy (SF=3.9 and 2.8, re-
spectively). In this model, the number of AFs is a critical
determinant of synergy.
How the SRAF mechanism may work is illustrated in
Figure 10D and E. A promoter-centred view is appropri-
ate here. When two or three transcription factors cooper-
ate, this means that they provide a promoter with two or
three AFs resulting in a gradually increased eﬃciency of
co-activator recruitment (Figure 10C), which is the clas-
sical text-book model. A single factor presenting one or
two AFs would in a similar fashion provide the promoter
with one or two AFs each contributing to an increased
eﬃciency of co-activator recruitment (Figure 10D and
E). From the point of view of the promoter, it must be
the total number and strengths of the associated AFs that
together determine its level of activation. With multiple
AFs per transcription factor, eﬃcient synergistic activa-
tion may be achieved with a more limited number of
factors than if each factor only carries single AFs.
Whether each of the AFs recruits the same (Figure 10D)
or diﬀerent co-activators (Figure 10E) might be promoter
dependent. For c-Myb, the full range of co-activators dif-
ferentially recruited remains to be determined. In all
variants of the model, diﬀential recruitment of
co-repressors or co-actviators leads to a diﬀerential chro-
matin signature.
We were not able to demonstrate a SUMO-dependent
co-repressor recruitment to wild-type c-Myb, despite its
moderate activity compared to the SUMO-deﬁcient 2KR
mutant. Still, there might be factors, not assayed in this
work, that show such a dependency also in a Myb context.
What is obvious, is that c-Myb does not mimic the behav-
iour of Sp3 in this system. We did however observe a clear
SUMO-dependent co-activator recruitment by showing a
signiﬁcantly higher p300 occupancy on a promoter to
which a SUMO-deﬁcient c-Myb is bound, compared to
the wild-type reference (Figure 9F). This diﬀerential re-
cruitment was mirrored in the expected change in the
local histone acetylation pattern (Figure 9G and H). We
believe this diﬀerential recruitment is linked to the switch
property of the SRAF in NRD. Exactly, how the
SUMO-negative NRD (SRAF in ON-state) contributes
to more eﬃcient p300 recruitment, remains to be
determined. A simple GST-pull-down experiment did
not reveal direct binding to p300, in a similar fashion as
the central TAD region (Supplementary Figure S4).
However, a Gal-NRD 2KR construct was found to be
p300 responsive in contrast to the corresponding
wild-type construct, consistent with a change in p300 re-
cruitment (Supplementary Figure S4). Our working hy-
pothesis is that the switch generates a novel interaction
with an unknown protein that also binds to p300, thus
leading to the observed diﬀerential p300 recruitment.
Eﬀorts are in progress to identify this factor.
A question worth asking is whether the SRAF model of
synergy is speciﬁc for c-Myb or reﬂecting a more general
mechanism. An argument for the latter is our observation
of a robust SRAF in the ID region of Sp3 and a more
moderate one in the CRD region of p53. This model may
well be relevant also for nuclear receptors (NRs). Many
NRs have at least two activation domains, the
ligand-independent AF, AF1, which resides in the
N-terminal domain, and the ligand-dependent, AF2,
which is localized in the C-terminal domain. Taking GR
as example, the AF1 region (amino acids 108 to 317) is
sumoylated (K298 and K313) and is subjected to SC (9).
Assuming then that AF1 may be switched on or oﬀ de-
pending sumoylation status, while AF2 is turned on upon
ligand binding, this represents an interesting equivalent to
c-Myb with the potential to act with diﬀerent numbers of
AFs in a SUMO-controlled manner. In fact, both the GR
AF1 and the AR AF1 have been shown to be switched on
when desumoylated (51,52).
In this study of how SUMO-conjugation restricts the
synergy behaviour of c-Myb, we have discovered a novel
switchable function (SRAF) associated with NRD,
providing c-Myb with a potential strong regulatory
switch. This switch is associated with a
SUMO-dependent co-activator recruitment changing the
local chromatin signature.
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